About Stilla Technologies, a Biotechnology Company
About Us
Stilla Technologies, founded in 2013 as a multiplex digital PCR company, is now part of Bio-Rad Laboratories. With more than a decade of experience transforming complex genomic data into actionable insights, Stilla supports a wide range of research and clinical applications — including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing.
Stilla’s groundbreaking Crystal Digital PCR™ solution, the QX700TM series systems (formerly the Nio® system), is the industry’s first digital PCR system featuring six fluorescent channels — offering the highest multiplexing and detection capacity available to biomedical researchers and clinicians.
Stilla maintains U.S. headquarters in San Diego, CA; European headquarters in Paris, France; and strategic partnerships across China, Europe, the Middle East, and Africa. In partnership with Bio-Rad Laboratories, we are committed to advancing health research through high-precision genetic analysis solutions for researchers and clinicians worldwide.
Our Mission
Improve health by offering high precision genetic analysis solutions to researchers and clinicians worldwide
At Stilla Technologies, we continuously innovate and evolve technologically toward better human health outcomes. Our global team with multidisciplinary expertise shares a passion to develop new products for advanced genetic testing and analysis. Our expertise spans from microfluidics and chemistry to molecular biology and computer science.
Our product, the Nio® System, has been adopted by researchers & clinicians around the world to develop a wide range of genetic tests and molecular biology assays – including, but not limited to, liquid biopsy tests for cancer diagnostics, infectious diseases, and GMO detection.